The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Open accessAbstract
BACKGROUND: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies METHODS: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily) RESULTS: Serum thromboxane B(2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin CONCLUSIONS: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It can also antagonize the platelet inhibition induced by low dose aspirin and lessens its cardioprotective effect (46).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,267
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,572
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S. C., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,304
Self-citationThe X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,270
Patrono, C., Coller, B. S., Dalen, J. E., Gerald, G. A. F., Fuster, V., Gent, M., Hirsh, J., & Roth, G. J. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.39s · Cited by 961
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 931
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A. B., Barnett, J. W., Chow, J., Ramesha, C. S., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 620
Catella-Lawson, F., McAdam, B. F., Morrison, B. W., Kapoor, S. C., Kujubu, D. A., Antes, L. M., Lasseter, K. C., Quan, H., Gertz, B. J., & FitzGerald, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 596
Self-citation
Flagged first, then by citations
Research works printed but not linked: 7
- Singh G, 1999, J Rheumatol, 26, 18
- Patrignani P, 1999, J Physiol Pharmacol, 50, 661
- Pathmakanthan S, 1998, Ir Med J, 91, 58
- Patrignani P, 1994, J Pharmacol Exp Ther, 271, 1705
- Sciulli MG, Patrignani P, Seta F, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro. In: Proceedings of the 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications, Florence, Italy, June 4–8, 2000:38. abstract.
- Reilly IAG, 1987, Blood, 69, 180, 10.1182/blood.V69.1.180.180 · DOI
- Catella-Lawson F, 1999, J Pharmacol Exp Ther, 289, 735
Cited by
Sorted by citations
Items 501–600 of 1,000
Malloy, R. J., Kanaan, A. O., Silva, M. A., & Donovan, J. L. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.004 · Cited by 30
Galliard-Grigioni, K. S., & Reinhart, W. H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.042 · Cited by 29
Identifying determinants of variability to tailor aspirin therapy
Rocca, B., Dragani, A., & Pagliaccia, F. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.144 · Cited by 29
Gargiulo, G., Capodanno, D., Longo, G., Capranzano, P., & Tamburino, C. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.964687 · Cited by 31
Greenberg, J. D., Bingham, C. O., Abramson, S. B., Reed, G. W., Sebaldt, R. J., & Kremer, J. M. (2005) · Arthritis Care & Research · doi:10.1002/art.20905 · Cited by 29
Aspirin resistance: What, why and when?
Shantsila, E., Watson, T., & Lip, G. Y. H. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.08.009 · Cited by 29
Pain Management in the Hospitalized Patient
Li, J. M. W. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.11.003 · Cited by 29
Hunt, R. H., Choquette, D., Craig, B. N., DeAngelis, C., Habal, F. M., Fulthorpe, G., Stewart, J. I., Turpie, A. G. G., & Davis, P. J. (2007) · PubMed Central · Cited by 28
Vascular effects of nonsteroidal antiinflammatory drugs
Soubrier, M., Rosenbaum, D. H., Tatar, Z., Lahaye, C., Dubost, J., & Mathieu, S. (2013) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.12.002 · Cited by 28
Shibata, K., Akagi, Y., Nozawa, N., Shimomura, H., & Aoyama, T. (2017) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-017-0078-7 · Cited by 28
Christiansen, M., Grove, E. L., & Hvas, A. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1726096 · Cited by 28
Modified MCM-41 as a drug delivery system for acetylsalicylic acid
Vyskočilová, E., Luštická, I., Paterová, I., Machová, L., & Červený, L. (2014) · Solid State Sciences · doi:10.1016/j.solidstatesciences.2014.10.004 · Cited by 28
Lanas, Á., Benito, P., Alonso, J. J., Hernández‐Cruz, B., Barón‐Esquivias, G., Pérez‐Aísa, Á., Calvet, X., García-Llorente, J. F., Gobbo, M., & González‐Juanatey, J. R. (2014) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2013.10.008 · Cited by 28
Yang, Q., Shi, M., Shen, Y., Cao, Y., Zuo, S., Zuo, C., Zhang, H., Gabrilovich, D. I., Yu, Y., & Zhou, J. (2014) · Blood · doi:10.1182/blood-2014-03-559658 · Cited by 28
Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel
Fiorella, D. J. (2010) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis.2009.001859 · Cited by 28
Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus
Avalos, I., Chung, C. P., Oeser, A. M., Milne, G. L., Borntrager, H. L., Morrow, J. D., Raggi, P., Solus, J. F., & Stein, C. M. (2007) · Lupus · doi:10.1177/0961203307083313 · Cited by 28
Prostanoids in the pathophysiology of human coronary artery
Özen, G., & Norel, X. (2017) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2017.03.003 · Cited by 29
Moreira, R., Jervis, P. J., Carvalho, A., Ferreira, P. M. T., Martins, J. A., Valentão, P., Andrade, P. B., & Pereira, D. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020122 · Cited by 28
Treatment of blunt cerebrovascular injuries: Anticoagulants or antiplatelet agents?
Hanna, K., Douglas, M. J., Asmar, S., Khurrum, M., Bible, L. E., Castañón, L., Ditillo, M. F., Kulvatunyou, N., & Joseph, B. A. (2020) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000002704 · Cited by 28
Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs
Maillard, M. P., & Burnier, M. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.83 · Cited by 28
Cyclooxygenase-2 Inhibition and Coagulation
Steffel, J., scher, T. F. L., Ruschitzka, F. T., & Tanner, F. C. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00004 · Cited by 30
Abramson, S. B. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10609 · Cited by 28
The Aspirin Resistance Controversy
Freedman, J. E. (2006) · Circulation · doi:10.1161/circulationaha.106.635847 · Cited by 28
Dretzke, J., Riley, R. D., Lordkipanidzé, M., Jowett, S. M., O’Donnell, J., Ensor, J., Moloney, E., Price, M. J., Raichand, S., Hodgkinson, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19370 · Cited by 28
Greenberg, J. D., Fisher, M., Kremer, J. M., Chang, H., Rosenstein, E. D., Kishimoto, M., Lee, S., Yazıcı, Y., Kavanaugh, A., & Abramson, S. B. (2009) · PubMed · Cited by 27
Gibson, C. M., Pride, Y. B., Aylward, P. E., Col, J. J., Goodman, S. G., Gulba, D. C., Bergovec, M., Kunadian, V., Zorkun, C. S., Buros, J. L., et al. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-008-0264-4 · Cited by 28
Scanzello, C. R., Moskowitz, N. K., & Gibofsky, A. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0009-6 · Cited by 27
Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE
Achilles, A., Mohring, A., Dannenberg, L., Piayda, K., Levkau, B., Hohlfeld, T., Zeus, T., Kelm, M., & Polzin, A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.122 · Cited by 27
Pharmacodynamic effects of Dan-hong injection in rats with blood stasis syndrome
Bi, C., Li, P., Liao, Y., Rao, H., Li, P., Yi, J., Wang, W.-Y., & Su, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109187 · Cited by 27
Gebrauch und potenzielle Risiken durch nicht verschreibungspflichtige Schmerzmittel
Freytag, A., Quinzler, R., Freitag, M., Bickel, H., Fuchs, A., Hansen, H., Hoefels, S., König, H. ‐., Mergenthal, K., Riedel-Heller, S. G., et al. (2014) · Der Schmerz · doi:10.1007/s00482-014-1415-5 · Cited by 27
Medikamente zur postoperativen Schmerztherapie: Bewährtes und Neues
Jage, J., Laufenberg–Feldmann, R., & Heid, F. M. (2008) · Der Anaesthesist · doi:10.1007/s00101-008-1326-x · Cited by 27
Advances in antiplatelet therapy
Jneid, H. M., & Bhatt, D. L. (2003) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.8.2.349 · Cited by 27
Munsterhjelm, E., Niemi, T., Ylikorkala, O., Silvanto, M., & Rosenberg, P. H. (2005) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2005.00707.x · Cited by 27
Davies, N. M., Teng, X. W., & Skjodt, N. M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342060-00004 · Cited by 27
Kim, P. S., & Reicin, A. S. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512719 · Cited by 27
Rocca, B., Tosetto, A., Petrucci, G., Rossi, E., Betti, S., Soldati, D., Iurlo, A., Cattaneo, D., Bucelli, C., Dragani, A., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27418 · Cited by 26
Friedewald, V. E., BENNETT, J. S., Christo, J. P., Pool, J. L., Scheiman, J. M., Simon, L. S., Strand, V., White, W. B., Williams, G. W., & Roberts, W. C. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.04.006 · Cited by 26
Patogênese e perspectivas de tratamento da Covid-19: uma revisão
Sousa, M. R. N., Barros, S. S., da Silva, M. M., Oliveira, A. P. M., Rocha, G. M. D. M., & de Oliveira, G. A. L. (2020) · Research Society and Development · doi:10.33448/rsd-v9i7.3730 · Cited by 26
Kawasaki Disease and Coronary Artery Involvement: A Narrative Review
Rajasekaran, K., Duraiyarasan, S., Adefuye, M. A., Manjunatha, N., & Ganduri, V. (2022) · Cureus · doi:10.7759/cureus.28358 · Cited by 26
Kunachowicz, D., Ściskalska, M., & Kepinská, M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20042813 · Cited by 26
Lanas, Á., Benito, P., Alonso, J. J., Hernández‐Cruz, B., Barón‐Esquivias, G., Pérez‐Aísa, Á., Calvet, X., García-Llorente, J. F., Gobbo, M., & González‐Juanatey, J. R. (2014) · Reumatología Clínica · doi:10.1016/j.reuma.2013.10.004 · Cited by 26
Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology
Hinz, B., & Brune, K. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.004 · Cited by 26
Engoren, M., Hadaway, J., Schwann, T. A., & Habib, R. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.050 · Cited by 26
Majeed, F., Kop, W. J., Poston, R., Kallam, S., & Mehra, M. R. (2009) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1441 · Cited by 26
Gastrointestinal lesions and complications of low-dose aspirin in the gastrointestinal tract
Sostres, C., & Gargallo, C. J. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.01.016 · Cited by 26
Anthocyanins in obesity-associated thrombogenesis: a review of the potential mechanism of action
Thompson, K., Pederick, W., & Santhakumar, A. B. (2016) · Food & Function · doi:10.1039/c6fo00154h · Cited by 26
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 27
Shantsila, E., & Lip, G. Y. H. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-47 · Cited by 26
Postprocedure Pain Management of Interventional Radiology Patients
Hatsiopoulou, O., Cohen, R., & Lang, E. V. (2003) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000085769.63355.24 · Cited by 26
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
Petrucci, G., Buck, G. A. N., Rocca, B., Parish, S., Baigent, C., Hatem, D., Mafham, M. M., Habib, A., Bowman, L. J., Armitage, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad868 · Cited by 28
Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects
Marcone, S., Dervin, F., & Fitzgerald, D. J. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12943 · Cited by 25
Shu, G., Chen, Y., Liu, T., Ren, S., & Kong, Y. (2018) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-018-9677-x · Cited by 25
Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin
Yokoyama, H., Ito, N., Soeda, S., Ozaki, M., Suzuki, Y., Watanabe, M., Kashiwakura, E., Kawada, T., Ikeda, N., Tokuoka, K., et al. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01373.x · Cited by 25
Lanas, Á., Benito, P., Alonso, J. J., Hernández‐Cruz, B., Barón‐Esquivias, G., Pérez‐Aísa, Á., Calvet, X., García-Llorente, J. F., Gobbo, M., & González‐Juanatey, J. R. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.11.014 · Cited by 29
Interactions between aspirin and COX‐2 inhibitors or NSAIDs in a rat thrombosis model
Umar, A., Boisseau, M., Yusup, A., Upur, H., Bégaud, B., & Moore, N. D. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00285.x · Cited by 25
The Future of Antiplatelet Therapy in Cardiovascular Disease
Patrono, C., & Rocca, B. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-020209-171035 · Cited by 25
Secondary Stroke Prevention: From Guidelines to Clinical Practice
Graham, G. D. (2008) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)31482-6 · Cited by 25
The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome
Kahraman, G., Şahı̇n, T., Kılıç, T., Baytuğan, N. Z., Ağaçdiken, A., Ural, E., Ural, D., & Komşuoğlu, B. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.10.025 · Cited by 25
NSAIDS and the risk of myocardial infarction: do they help or harm?
Bhatt, D. L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl090 · Cited by 25
de Castro, P. A., Urbano, L. M. F., & Costa, I. M. C. (2009) · Anais Brasileiros de Dermatologia · doi:10.1590/s0365-05962009000400002 · Cited by 24
Aspirin use and endometrial cancer risk: a meta-analysis and systematic review
Wang, Y., Zhao, J., Chen, X., Zhang, F., & Li, X. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.125 · Cited by 24
Sha, W., Olesch, C., Hanaka, H., Rådmark, O., Weigert, A., & Brüne, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.28181 · Cited by 24
Facts and controversies of aspirin and clopidogrel therapy
Faxon, D. P., & Freedman, J. E. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.11.019 · Cited by 24
Clinical pharmacology of etoricoxib
Capone, M. L., Tacconelli, S., & Patrignani, P. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.2.269 · Cited by 24
Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease
Bates, E., & Lau, W. C. (2005) · Circulation · doi:10.1161/01.cir.0000157158.63751.b2 · Cited by 24
Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women
Bavry, A. A., Thomas, F., Allison, M., Johnson, K., Howard, B. V., Hlatky, M. A., Manson, J. E., & Limacher, M. C. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000800 · Cited by 24
Nonsteroidal Anti-inflammatory Drugs, Acetaminophen, and COX-2 Inhibitors
Birmingham, B., & Buvanendran, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-08340-9.00040-2 · Cited by 24
Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove, E. L. (2012) · PubMed · Cited by 24
Secondary Stroke Prevention Strategies for the Oldest Patients
Bushnell, C., & Colon-Emeric, C. S. (2009) · Drugs & Aging · doi:10.2165/00002512-200926030-00003 · Cited by 25
Engoren, M., Habib, R., Zacharias, A., Dooner, J., Schwann, T. A., Riordan, C. J., Durham, S. J., & Shah, A. S. (2007) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2007.01.024 · Cited by 24
Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects
Loewen, P. S. (2002) · Canadian Journal of Emergency Medicine · doi:10.1017/s1481803500007508 · Cited by 24
New Advances in the Management of Endodontic Pa in Emergencies
Hargreaves, K., & Keiser, K. (2004) · Journal of the California Dental Association · doi:10.1080/19424396.2004.12223994 · Cited by 24
The Pharmacokinetics of Ibuprofen in Humans and Animals
Jamali, F., & Brocks, D. R. (2015) · doi:10.1002/9781118743614.ch4 · Cited by 24
Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies
Caccia, S., Garattini, S. K., Pasina, L., & Nobili, A. (2009) · Drug Safety · doi:10.2165/11316630-000000000-00000 · Cited by 24
What Is The “Safest” Non-Steroidal Anti-Inflammatory Drugs?
Hassan (2012) · Current Research in Medicine · doi:10.3844/amjsp.2012.115.123 · Cited by 23
FitzGerald, G. A. (2004) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000130685.73681.8b · Cited by 23
Self-citationMass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease
Mesaros, C., & Blair, I. A. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9121-1 · Cited by 23
Depta, J. P., & Bhatt, D. L. (2008) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256587 · Cited by 23
Time Course and Pattern of Blood Loss With Ibuprofen Treatment in Healthy Subjects
Bowen, B. M., Yuan, Y., James, C., Rashid, F., & Hunt, R. H. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00605-1 · Cited by 23
Insights from Continued Use of a Novacor Left Ventricular Assist System for a Period of 6 Years
Faggian, G. G., Santini, F., Franchi, G., Portner, P. M., & Mazzucco, A. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.12.115 · Cited by 23
Aspirin and Antiplatelet Agent Resistance
Greer, D. M. (2010) · CNS Drugs · doi:10.2165/11539160-0000000000-00000 · Cited by 23
Possible mechanisms of drug-induced aspirin and clopidogrel resistance
Schroeder, W. S., Ghobrial, L., & Gandhi, P. J. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-8670-y · Cited by 23
Crofford, L. J. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200205000-00005 · Cited by 23
Rational Use of Analgesic and Antiinflammatory Drugs
Crofford, L. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200112203452512 · Cited by 23
Mohammed, A.-S. Y., Dyab, A. K. F., Taha, F., & El‐Mageed, A. I. A. A. (2022) · RSC Advances · doi:10.1039/d2ra02888c · Cited by 24
Antiplatelet therapy and vascular disease: an update
Buch, M. H., Prendergast, B., & Storey, R. F. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710375780 · Cited by 22
Sakata, C., Kawasaki, T., Kato, Y., Abe, M., Suzuki, K., Ohmiya, M., Funatsu, T., Morita, Y., & Okada, M. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.03.005 · Cited by 22
Alqahtani, Z. A., & Jamali, F. (2018) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps29854 · Cited by 22
Son, M. B. F., & Sundel, R. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00035-1 · Cited by 22
El‐Nachef, N., Scheiman, J. M., Fendrick, A. M., Howden, C. W., & Chey, W. D. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03836.x · Cited by 22
4 years after withdrawal of rofecoxib: where do we stand today?
Jaksch, W., Dejaco, C., & Schirmer, M. (2008) · Rheumatology International · doi:10.1007/s00296-008-0650-4 · Cited by 22
DHAWAN, V. M., Schwalb, D. J., Shumway, M. J., Warren, M. C., Wexler, R. S., Zemtseva, I. S., Zifcak, B. M., & Janero, D. R. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.06.011 · Cited by 22
Balancing Risks and Benefits of Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs
Scheiman, J. M. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.03.006 · Cited by 22
Guthikonda, S., Mangalpally, K. K. R., Patel, R. T., DeLao, T., Bergeron, A. L., Dong, J.-F., Lev, E. I., Vaduganathan, M., & Kleiman, N. S. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-10-0590 · Cited by 22
Drug–drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity
Nalamachu, S. R., Pergolizzi, J. V., Raffa, R. B., Lakkireddy, D., & Taylor, R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.924924 · Cited by 21
Patrício, J. P. H., Barbosa, J., Ramos, R. M. M., Antunes, N. F. P., & de Melo, P. C. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0052-6 · Cited by 23
Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Alhazzani, A. A., Venkatachalapathy, P., Padhilahouse, S., Sellappan, M., Munisamy, M., Sekaran, M., & Kumar, A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.667234 · Cited by 21
Variability of Platelet Indices and Function: Acquired and Genetic Factors
de Gaetano, G., Santimone, I., Gianfagna, F., Iacoviello, L., & Cerletti, C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-29423-5_16 · Cited by 24
Intake of dissolved organic matter from deep seawater inhibits atherosclerosis progression
Radhakrishnan, G., Yamamoto, M., Maeda, H., Nakagawa, A., KatareGopalrao, R., Okada, H., Nishimori, H., Wariishi, S., Toda, E., Ogawa, H., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.073 · Cited by 21
Recurrent Stroke while on Antiplatelet Therapy
John, S., & Katzan, I. L. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.12.007 · Cited by 20
Metadata
- Authors
- Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A.
- Affiliations
- University of Pennsylvania (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-12-20
- Volume
- 345
- Issue
- 25
- Pages
- 1809-1817
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2011327495
- Cited by
- 1,394
- References
- 44
- Citations by year
- 2026: 19 · 2025: 15 · 2024: 18 · 2023: 18 · 2022: 33 · 2021: 43 · 2020: 33 · 2019: 40 · 2018: 40 · 2017: 46 · 2016: 41 · 2015: 56 · 2014: 46 · 2013: 69 · 2012: 79
- FWCI
- 50.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL 5400, HL62250, P01HL062250)
- National Center for Research Resources (M01-RR-00040, M01RR000040)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- aspirin, ibuprofen, cyclooxygenase inhibitors, rofecoxib, diclofenac, paracetamol, drug interactions, platelet aggregation, thromboxane B2, antiplatelet activity, nonsteroidal anti-inflammatory drugs, arthritis treatment, cardiovascular risk, cardioprotection
- MeSH terms
- Acetaminophen, Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Diclofenac, Drug Interactions, Drug Therapy, Combination, Humans, Ibuprofen, Isoenzymes, Lactones, Membrane Proteins, Middle Aged, Platelet Aggregation, Platelet Aggregation Inhibitors, Prostaglandin-Endoperoxide Synthases, Sulfones, Thromboxane B2, Dinoprostone, Cyclooxygenase Inhibitors, Cross-Over Studies, Analgesics, Non-Narcotic, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
